within Pharmacolibrary.Drugs.ATC.A;

model A16AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 120 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Mercaptamine (also known as cysteamine) is a sulfhydryl compound indicated primarily in the treatment of nephropathic cystinosis. It is used to reduce cystine accumulation within the lysosomes of various tissues. Mercaptamine may also have use as an adjuvant in radiation exposure and other cystine-related disorders. It is an approved medicine and marketed mainly as oral capsules, but also available as ophthalmic solution for ocular complications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for mercaptamine in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Chiew, AL, et al., &amp; Buckley, NA (2018). Interventions for paracetamol (acetaminophen) overdose. <i>The Cochrane database of systematic reviews</i> 2(2) CD003328–None. DOI:<a href=&quot;https://doi.org/10.1002/14651858.CD003328.pub3&quot;>10.1002/14651858.CD003328.pub3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29473717/&quot;>https://pubmed.ncbi.nlm.nih.gov/29473717</a></p></li><li><p>Devereux, G, et al., &amp; O&#x27;Neil, D (2016). An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis. <i>Clinical drug investigation</i> 36(8) 605–612. DOI:<a href=&quot;https://doi.org/10.1007/s40261-016-0405-z&quot;>10.1007/s40261-016-0405-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27153825/&quot;>https://pubmed.ncbi.nlm.nih.gov/27153825</a></p></li><li><p>Atallah, C, et al., &amp; Greige-Gerges, H (2020). Challenges for cysteamine stabilization, quantification, and biological effects improvement. <i>Journal of pharmaceutical analysis</i> 10(6) 499–516. DOI:<a href=&quot;https://doi.org/10.1016/j.jpha.2020.03.007&quot;>10.1016/j.jpha.2020.03.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33425447/&quot;>https://pubmed.ncbi.nlm.nih.gov/33425447</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AA04;
